Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $882M | $1.04B | $976M | $963M | $943M | $1.09B | $1.13B | $1.13B | $1.14B | $1.09B |
| Revenue growth | — | 18.0% | -6.3% | -1.3% | -2.0% | 15.2% | 3.8% | -0.2% | 1.1% | -4.3% |
| Gross profit | $500M | $577M | $556M | $552M | $547M | $621M | $625M | $624M | $634M | $596M |
| Gross margin | 56.7% | 55.4% | 56.9% | 57.3% | 58.0% | 57.1% | 55.4% | 55.5% | 55.8% | 54.7% |
| Operating income | $206M | $215M | $67.5M | $291M | $297M | $330M | -$22.4M | $342M | $337M | $309M |
| Operating margin | 23.3% | 20.7% | 6.9% | 30.2% | 31.5% | 30.4% | -2.0% | 30.4% | 29.6% | 28.4% |
| Net income | $69.4M | $340M | -$35.8M | $142M | $165M | $205M | -$82.3M | $209M | $215M | $190M |
| Net margin | 7.9% | 32.6% | -3.7% | 14.8% | 17.5% | 18.9% | -7.3% | 18.6% | 18.9% | 17.5% |
| EPS (diluted) | $1.30 | $6.34 | -$0.69 | $2.78 | $3.25 | $4.04 | -$1.65 | $4.17 | $4.29 | $3.91 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $149M | $210M | $189M | $217M | $236M | $260M | $230M | $249M | $252M | $258M |
| Capital expenditures | $2.98M | $12.5M | $10.5M | $14.6M | $22.2M | $9.64M | $7.78M | $9.55M | $8.22M | $11.2M |
| Free cash flow | $146M | $198M | $179M | $203M | $213M | $250M | $222M | $239M | $243M | $246M |
| Share buybacks | $0.00 | $0.00 | $50.0M | $56.7M | $11.9M | $0.00 | $50.0M | $25.0M | $51.5M | $156M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $41.9M | $32.5M | $27.5M | $94.8M | $32.3M | $27.2M | $58.5M | $46.5M | $97.9M | $63.9M |
| Total assets | $3.91B | $3.76B | $3.44B | $3.51B | $3.43B | $3.67B | $3.35B | $3.32B | $3.40B | $3.49B |
| Total liabilities | $3.09B | $2.58B | $2.35B | $2.34B | $2.07B | $2.09B | $1.91B | $1.66B | $1.57B | $1.61B |
| Long-term debt | $2.19B | $1.99B | $1.80B | $1.73B | $1.48B | $1.48B | $1.35B | $1.13B | $992M | $994M |
| Shareholders' equity | $823M | $1.18B | $1.10B | $1.17B | $1.36B | $1.58B | $1.45B | $1.66B | $1.83B | $1.89B |
| Retained earnings | $397M | $736M | $702M | $844M | $1.01B | $1.21B | $1.13B | $1.34B | $1.56B | $1.75B |
| Shares (wtd avg diluted) | 53.4M | 53.5M | 52.1M | 51.1M | 50.6M | 50.8M | 49.9M | 50.2M | 50.1M | 48.7M |
Every figure is extracted from Prestige Consumer Healthcare Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.